Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system

被引:108
|
作者
Zhang, J [1 ]
Hughes, SE [1 ]
机构
[1] UCL, City Hosp NHS Trust, Royal Free & Univ Coll, Med Sch,Dept Pathol, London WC1E 6JJ, England
关键词
eph; ephrin; angiogenesis; receptor tyrosine kinase; signal transduction; endothelial cell;
D O I
10.1002/path.1937
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiogenesis is a highly complex orchestrated process that plays a critical role in normal development and in the pathophysiology of multiple disease processes, including tumour neovascularization, ischaemic recovery, and wound healing. In recent years there has been a resurgence of interest in Eph receptors and their ligands, ephrins, as their participation in vasculogenesis and angiogenesis has become apparent. The Eph receptor family is the largest family of receptor tyrosine kinases identified to date. The Eph receptors and their membrane-anchored ligands, ephrins, are unique in that they mediate bi-directional signalling. This is concomitant with activation of the Eph receptor tyrosine kinase domain and transduction of the typical forward signal into the receptor-bearing cell. The ligand-receptor interaction also leads to transduction of a reverse signal into the ephrin-bearing cell. The Eph/ephrin signalling mechanism is responsible for diverse and complex biological functions mediated by Eph receptors and ephrin ligands. These include vascular development, tissue-border formation, cell migration, axon guidance, and synaptic plasticity. The role of Eph receptors and ephrins in the processes of development of the cardiovascular system, angiogenesis, and vascular remodelling has been the subject of intense investigation since they were first identified in 1987. This review addresses the role of this new growth factor receptor tyrosine kinase family in those processes and provides new insights into the way in which Eph receptors and ephrin ligands modulate the angiogenic response and participate in vascular remodelling and vascular boundary formation during development of the cardiovascular system and vascularization of cancer. Copyright (c) 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:453 / 461
页数:9
相关论文
共 50 条
  • [31] mRNA expression of ephrins and Eph receptor tyrosine kinases in the neonatal and adult mouse central nervous system
    Liebl, DJ
    Morris, CJ
    Henkemeyer, M
    Parada, LF
    JOURNAL OF NEUROSCIENCE RESEARCH, 2003, 71 (01) : 7 - 22
  • [32] Tyrosine Phosphoproteomics of Patient-Derived Xenografts Reveals Ephrin Type-B Receptor 4 Tyrosine Kinase as a Therapeutic Target in Pancreatic Cancer
    Renuse, Santosh
    Madamsetty, Vijay S.
    Mun, Dong-Gi
    Madugundu, Anil K.
    Singh, Smrita
    Udainiya, Savita
    Mangalaparthi, Kiran K.
    Kim, Min-Sik
    Liu, Ren
    Kumar, S. Ram
    Krasnoperov, Valery
    Truty, Mark
    Graham, Rondell P.
    Gill, Parkash S.
    Mukhopadhyay, Debabrata
    Pandey, Akhilesh
    CANCERS, 2021, 13 (14)
  • [33] Heritability and role for the environment in DNA methylation in AXL receptor tyrosine kinase
    Breton, Carrie V.
    Salam, Muhammad T.
    Gilliland, Frank D.
    EPIGENETICS, 2011, 6 (07) : 895 - 898
  • [34] The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome
    Yang, Wenli
    Zhang, Junlan
    Hu, Bingqian
    Wu, Wei
    Venter, Julie
    Alpini, Gianfranco
    Fallon, Michael B.
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2014, 306 (01): : G72 - G80
  • [35] Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
    Mendel, DB
    Laird, AD
    Smolich, BD
    Blake, RA
    Liang, CX
    Hannah, AL
    Shaheen, RM
    Ellis, LM
    Weitman, S
    Shawver, LK
    Cherrington, JM
    ANTI-CANCER DRUG DESIGN, 2000, 15 (01): : 29 - 41
  • [36] IDENTIFICATION OF FULL-LENGTH AND TRUNCATED FORMS OF EHK-3, A NOVEL MEMBER OF THE EPH RECEPTOR TYROSINE KINASE FAMILY
    VALENZUELA, DM
    ROJAS, E
    GRIFFITHS, JA
    COMPTON, DL
    GISSER, M
    IP, NY
    GOLDFARB, M
    YANCOPOULOS, GD
    ONCOGENE, 1995, 10 (08) : 1573 - 1580
  • [37] The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications
    Wium, Martha
    Ajayi-Smith, Aderonke F.
    Paccez, Juliano D.
    Zerbini, Luiz F.
    CANCERS, 2021, 13 (07)
  • [38] Role of G protein-coupled receptor kinase 2 in tumoral angiogenesis
    Rivas, Veronica
    Nogues, Laura
    Reglero, Clara
    Mayor, Federico, Jr.
    Penela, Petronila
    MOLECULAR & CELLULAR ONCOLOGY, 2014, 1 (04):
  • [39] Role of the receptor tyrosine kinase Axl in hepatocellular carcinoma and its clinical relevance
    Niu, Zhao-Shan
    Niu, Xiao-Jun
    Wang, Wen-Hong
    FUTURE ONCOLOGY, 2019, 15 (06) : 653 - 662
  • [40] The receptor tyrosine kinase EphB4 and ephrin-B ligands restrict angiogenic growth of embryonic veins in Xenopus laevis
    Helbling, PM
    Saulnier, DME
    Brändli, AW
    DEVELOPMENT, 2000, 127 (02): : 269 - 278